Rudolf de Boer


Rudolf de Boer (1972, Gouda, the Netherlands) is a Clinical Cardiologist and a Professor of Translational Cardiology at the University Medical Center Groningen, the Netherlands.

Doctor de Boer’s clinical interests are cardiogenetics, echocardiography and end-stage heart failure including VAD therapy and transplant.   Professor de Boer has several research lines, and has authored over 350 articles. He received grants from the Netherlands Heart Foundation, the Dutch Organization for Scientific Research, and the European Research Council (ERC). He was appointed a Fellow of the European Society of Cardiology (ESC) in 2010. He has served as the president of the Heart Failure Working Group of the Dutch Society of Cardiology from 2014-2019, and since 2014 is Board Member of the Heart Failure Association (HFA) of the ESC. He is coordinator of the HFA committee on Heart Failure with Preserved Ejection Fraction (HFpEF) and co-coordinator of the Translational Committee. He is member of the ESC Education, Advocacy, and eHealth committees.

Contact details

Current activities

The group of Rudolf de Boer works in translational cardiology, with a focus on heart failure, aiming to uncover novel pathways, proteins and biomarkers to better understand the pathophysiology. The projects span from experimental studies all the way to clinical studies.

Current projects

European Research Council (ERC):

SECRETE-HF: It has been recognized that cancer may develop in response to cancer treatments. However, herein, we have showed for the first time that cancer is more prevalent in patients with heart failure and CV disease. This is an entirely new field with a large number of subprojects, from cell studies to animal studies, but also including patient cohorts.

Collaborators: Professor Alexander Lyon (Imperial College, London, UK), Professor Javid Moslehi (Nashville University, Tennessee, USA), and Professor Rienk Nieuwland (Amsterdam UMC).


Heart Foundation:

CVON-DOSIS:  Studies into protein quality control in cardiomyopathies. National collaboration with Amsterdam and Utrecht. Collaborators: Professor Jolanda van der Velden (Amsterdam UMC); Professor Folkert Asselbergs (UMC Utrecht) and Professor Peter van Tintelen (UMC Utrecht).

CVON SHE-PREDICTS-HF: Sex-specific predictors of new onset heart failure. We make use of large community dwelling cohorts, with a large number of cardiovascular biomarkers. Collaborators: Dr. Vannessa van Empel, Professor Stephane Heymans & Professor Blanche Schroen (Maastricht UMC).

CVON RED CVD: Early detection of heart failure, atrial fibrillation and coronary artery disease is difficult and suboptimal in primary care. This project includes a cluster randomized trial in primary care practices in an effort to optimize early recognition.  Collaborators: Professor Frans Rutten (Julius Center & UMC Utrecht), Professor Arno Hoes (UMC Utrecht).

PREDICT-2: Consortium working on sudden cardiac death. We will study mutations in phospholamban as a cause for sudden death. Collaborators: Professor Arthur Wilde (Amsterdam UMC), Professor Mark Vos (UMC Utrecht), Professor Paul Volders (Maastricht UMC).


Clinical trials:

My group has several clinical studies in its portfolio, usually in line with our other scientific projects. I have been Dutch National lead on the DAPA-HF trial, a landmark trial with the SGLT2 inhibitor in heart failure. I am member of the executive committee of DELIVER, that studies dapagliflozin in HFpEF. Furthermore, I have been studying biomarkers in heart failure, and am co-PI of the MONITOR HF study, a study that evaluates the pulmonary artery pressure monitor in severe heart failure.


LeDucq Foundation:

CURE-PLaN: In our part of the country, we have a high prevalence of cardiomyopathy due to a founder mutation in the phospholamban (PLN) gene. We have secured substantial funding to work on several aspects of the PLN gene. For more information, go to this page.

My projects


Predicting new-onset heart failure in women


Secreted factors in cardiac remodeling provoke tumorigenesis and end organ damage in heart failure


PHOspholamban RElated CArdiomyopathy STudy


Improving early detection of CVD

PLN cardiomyopathy

Investigating and treating phospholamban cardiomyopathy


Facilitate personalized therapies in patients with heart failure


Stem cell models to unravel the susceptibility and resilience to develop heart failure


MITOchondrial therapy to increase cardiac FORCE and enhance exercise performance


Personalised Medicine in Chronic Disease Management

My publications

Sex-Specific Associations of Cardiovascular Risk Factors and Biomarkers with Incident Heart Failure

Navin Suthahar, Emily S. Lau, Michael J. Blaha, Samantha M. Paniagua, Martin G. Larson, Bruce M. Psaty, Emelia J. Benjamin, Matthew A. Allison, Traci M. Bartz, James L. Januzzi Jr., Daniel Levy, Laura M.G. Meems, Stephan J.L. Bakker, Joao A.C. Lima, Mary Cushman, Douglas S. Lee, Thomas J. Wang, Christopher R. deFilippi, David M. Herrington, Matthew Nayor, Ramachandran S. Vasan, Julius M. Gardin, Jorge R. Kizer, Alain G. Bertoni, Norrina B. Allen, Ron T. Gansevoort, Sanjiv J. Shah, John S. Gottdiener, Jennifer E. Ho and Rudolf A. de Boer

view online: Journal of the American College of Cardiology

Sex-related differences in contemporary biomarkers for heart failure: a review.

Suthahar N, Meems LMG, Ho JE, de Boer RA. Eur J Heart Fail. 2020.

view on PubMed

High-sensitivity Troponin-T and Cardiovascular Outcomes in the Community: Differences between Women and Men.

Suthahar N, Meems LMG, van Veldhuisen DJ, Walter JE, Gansevoort RT, Heymans S, Schroen B, van der Harst P, Kootstra-Ros JE, van Empel V, Mueller C, Bakker SJL, de Boer RA. Mayo Clin Proc. 2020.

Available on PubMed

Sex-specific associations of obesity and N-Terminal Pro-B-Type Natriuretic Peptide levels in the general population

Navin Suthahar, Wouter C Meijers, Jennifer E Ho, Ron T Gansevoort, Adriaan A Voors, Peter van der Meer, Stephan J L Bakker, Stephane Heymans, Vanessa van Empel, Blanche Schroen, Pim van der Harst, Dirk J van Veldhuisen, and Rudolf A de Boer. Eur J Heart Fail. 2018.

view on PubMed

Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction.

de Boer RA, Nayor M, deFilippi CR, Enserro D, Bhambhani V, Kizer JR, Blaha MJ, Brouwers FP, Cushman M, Lima JAC, Bahrami H, van der Harst P, Wang TJ, Gansevoort RT, Fox CS, Gaggin HK, Kop WJ, Liu K, Vasan RS, Psaty BM, Lee DS, Hillege HL, Bartz TM, Benjamin EJ, Chan C, Allison M, Gardin JM, Januzzi JL Jr, Shah SJ, Levy D, Herrington DM, Larson MG, van Gilst WH, Gottdiener JS, Bertoni AG, Ho JE. JAMA Cardiol. 2018

view on publisher site